Nanocor, Ltd is a biotech startup established in 2011 in Tomsk, Russia that conducts research on developing hybrid organic-inorganic nanoparticles to treat atherosclerosis and lipid disorders, having received patents and becoming a resident at the Skolkovo Innovation Centre; preliminary experiments show the nanoparticles can selectively bind cholesterol crystals and lipids and accumulate in plaque without toxicity.

1. Nanocor, Ltd
Nanocor, Ltd was established on November 11, 2011.
Nanocor, Ltd conducts translational research aimed at development and marketing of novel Nanoscience-
based products for prevention and treatment of arterial atherosclerosis and blood lipid spectrum
disorders.
Co-executors:
The Federal State Budgetary Institution “Research Institute for Cardiology” of Siberian Branch under the
Russia Academy of Medical Sciences, Tomsk, Russia
The National Research Tomsk Polytechnic University, Tomsk, Russia
Activities
Nanocor, Ltd launched drug discovery project
Proof of mechanism studies suggested that biocompatible organic-inorganic hybrid nanoparticles (HNP)
can selectively bind to cholesterol crystals in atherosclerotic plaque without disrupting lipid rafts of live
cells. HNP induce physicochemical modification of cholesterol crystals by affecting the long-range
intermolecular order. HNP increase bioavailability of cholesterol and promote the dissolution of the
cholesterol crystals. HNP can also bind to blood lipoproteins providing a new way for blood purification
therapy.
Research
The preliminary experiments were conducted in three directions:
I. Binding lipid components in blood, plasma, and serum:
The first set of in-vitro experiments provided evidence for selective binding of lipids by HNP. The
experiments showed that custom-designed HNP were effective at absorbing specific lipid components in
blood lipid spectrum.
II. Accumulation of HNP in human atherosclerotic plaque tissue:
The second set of experiments addressed HNP ability to penetrate deep into the human atherosclerotic
plaque isolated from human aortas and femoral arteries during prosthetic surgery.
III. Safety of NP administration:
The preliminary experiments showed that the life-time daily oral administration of the original carbon-
covered nanoparticles did not have significant impact on health of experimental animals.
Further studies are required to elucidate the cellular and molecular mechanisms of HNP-induced
transformation of the atherosclerotic plaque material. Safe and effective modes for topical delivery of HNP
should be further identified. The key attention will be given to the development of the methods for
controlled delivery (eluting) of HNP from vascular stents and other topical applicators. Additional research
is needed to establish the full range of correlations between HNP modifications and selectivity of HNP
binding to different lipid components in biological tissues and liquids.
Patents
Nanocor, Ltd, in a partnership with the co-executors, has developed and patented technology for
construction of biocompatible organic-inorganic hybrid nanoparticles (HNP) to use them as an agent in
treatment, diagnostics, and prevention of cholesterol crystal-related diseases such as arterial
atherosclerosis. RF patents ## 2405655 and 2406015.

2. Becoming a Skolkovo Resident
Nanocor, Ltd became a resident of the Biomedical Cluster of the Skolkovo Innovation Centre on
December, 2011. And now we are searching a potential investment that makes support in share of 25%
our project had previously approved by Fund of Skolkovo.
Technological Entrepreneurship and Innovation
Business Project Development: Summer School, 2012
Executive Summer School,
Research team of Nanocor, Ltd received education grant and attended the
2012: Technological Entrepreneurship and Innovation Business Project Development.
Website
Looking for funding
Grant amount
Co-investments
Location Tomsk, Russia
Email Shamil@cardio.tsu.ru
Market
Among our potential clients are private and government-funded specialized medical centers,
pharmaceutical and biotech companies, and academic institutions. Time to market depends on the
product (2 – 12 years).
Company
Nanocor, Ltd conducts translational research aimed at development and marketing of novel Nanoscience-
based products for prevention and treatment of arterial atherosclerosis and blood lipid spectrum
disorders. To comply with GLP and GMP, the company plans to work with CRO in the leading specialized
research centers.
Investment opportunities
Nanocor, Ltd works on developing of several products, including:
• Bulk HNP for pharmaceutical and biotech companies
• HNP as an agent for atherosclerotic plaque removal
• HNP-eluting stents
• HNP-based cartridges for blood purification therapy
• Technology for HNP construction
The projects are into various stages of completion from proof of mechanism studies to prototype
manufacturing.

3. Te
eam
Profe
essor Shamil D. Akhmedo MD, DSc
ov, c
Direc of Nanoc Ltd
ctor cor,
Depu Director fo Innovation and Strateg Developm
uty or n gic ment, Research Institute f Cardiolog
for gy
Reseearch area: cardiovascula surgery
ar
Profe
essor Victor D Filimonov, DSc
D.
Head of the Depa
d artment of Bio
oengineering and Organic Synthesis
g
Toms Polytechnic University
sk y
Reseearch area: fine organic synthesis
s
Profe
essor Sergey A. Afanasye MD, PhD DMS
y ev, D,
Reseearch Consultant
Head of the Molecular and Ce
d ellular Pathollogy and Gene Diagnosti Laborator
ics ry
Reseearch Institute for Cardiolo
e ogy
Reseearch area: cellular pathoology and gen diagnostic
ne cs

4. Assis
stant Profess Pavel Pos
sor stnikov, PhD
D
Reseearch Consultant
Toms Polytechnic University
sk y
Reseearch area: fine organic synthesis
s
Assis
stant Profess Marina Tr
sor rusova, PhD
Reseearch Consultant
Toms Polytechnic University
sk y
Reseearch area: fine organic synthesis
s
Tatiana Rebrova, PhD
Reseearch Consultant